Expression of IL-33 and its epigenetic regulation in multiple sclerosis

Annals of Clinical and Translational Neurology

Volumn 1, Issue 5, 2014, Pages 307-318

  Zhang, Fanglin ^a   Tossberg, John T ^a   Spurlock, Charles F ^a   Yao, Song Yi ^a   Aune, Thomas M ^a   Sriram, Subramaniam ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 OLIGOADENYLATE SYNTHASE 1; ACTB PROTEIN; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; B2M PROTEIN; CSF3R PROTEIN; CTSS PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EXT2 PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE DEACETYLASE 3; HLA DR ANTIGEN; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 33; LETHAL (2) GIANT LARVAE PROTEIN HOMOLOG 2; LIPOPOLYSACCHARIDE; PEPTIDES AND PROTEINS; PGK1 PROTEIN; PMAIP1 PROTEIN; PROTEIN FOS; PROTEIN P53; STEROID RECEPTOR COACTIVATOR 3; TATA BINDING PROTEIN ASSOCIATED FACTOR; TGF BETA RECEPTOR TYPE 2; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR POU; TRANSCRIPTION FACTOR POU6F1; TRANSFORMING GROWTH FACTOR BETA2; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 84969421982     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.47     Document Type: Article

References (42)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502–1517.
2. Lassmann H. The architecture of inflammatory demyelinating lesion in MS: implications for studies on pathogenesis. Neuropathol Appl Neurol 2011;37:698–710.
3. Frohman EM, Racke MK, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 2006;354:942–955.
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683–747.
5. Crooke PS, Tossberg JT, Horst SN, et al. Using gene expression data to identify certain gastro-intestinal diseases. J Clin Bioinforma 2013;2:20.
6. Hudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008;84:631–643.
7. Christophi GP, Gruber RC, Panos M, et al. Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol 2012;142:308–319.
8. Tossberg JT, Crooke PS, Henderson MA, et al. Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes Immun 2011;13:146–154.
9. Tossberg JT, Crooke PS, Henderson MA, et al. Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis. J Clin Bioinforma 2013;3:18.
10. Yasuda K, Muto T, Kawagoe T, et al. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci USA 2012;109:3451–3456.
11. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2011;10:103–110.
12. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011;7:321–329.
13. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827–840.
14. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479–490.
15. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007;104:282–287.
16. Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008;9:1006–1012.
17. Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011;186:4375–4387.
18. Kuchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008;173:1229–1242.
19. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20–38.
20. Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol 2009;86:769–778.
21. Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551–2555.
22. Jiang HR, Milovanovic M, Allan D, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 2012;42:1804–1814.
23. Gray SG, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006;1:67–75.
24. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349–352.
25. Kondo T, Raff M. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 2004;18:2963–2972.
26. Shakespear MR, Halili MA, Irvine KM, et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011;32:335–343.
27. Zhang F, Shi Y, Wang L, Sriram S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS ONE 2011;6:e16795.
28. Chen X, Barozzi I, Termanini A, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci USA 2012;109:E2865–E2874.
29. Ali S, Mohs A, Thomas M, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 2011;187:1609–1616.
30. Maas K, Chen H, Shyr Y, et al. Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. Hum Mol Genet 2005;14:1305–1314.
31. Maas K, Westfall M, Pietenpol J, et al. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis Rheum 2005;52:1047–1057.
32. Wills-Karp M, Rani R, Dienger K, et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med 2012;209:607–622.
33. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008;255(Suppl 1):3–11.
34. Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196–4202.
35. Roger T, Lugrin J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011;117:1205–1217.
36. Sun Y, Leaman DW. Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem 2005;280:15561–15568.
37. Yakovlev AG, Di Giovanni S, Wang G, et al. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004;279:28367–28374.
38. Wang A, Kurdistani SK, Grunstein M. Requirement of Hos2 histone deacetylase for gene activity in yeast. Science 2002;298:1412–1414.
39. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9:206–218.
40. Mullican SE, Gaddis CA, Alenghat T, et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 2012;25:2480–2488.
41. Ye F, Chen Y, Hoang T, et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 2009;12:829–838.
42. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.